{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/epilepsy/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"7a679807-bda2-5ee7-9bde-7ecdc0762be8","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 2323e016-02bf-4581-8410-44bea0c6d176 --><h2>Changes</h2><!-- end field 2323e016-02bf-4581-8410-44bea0c6d176 -->","summary":null,"htmlStringContent":"<!-- begin item 7a7fd4ac-984b-469f-a677-36bbbbdd2e19 --><!-- begin field 62582180-70bc-4710-96c2-1219ceee87db --><p><strong>January 2021 </strong>— minor update. The safety profile of valproate in paediatrics has been updated in line with revised manufacturer's SPC.</p><p><strong>November 2020 </strong>— minor update. A typographical error has been corrected.</p><p><strong>August 2020 </strong>— minor update. Adverse effects of antiepileptic drugs updated to contain information on exacerbation of seizures.</p><p><strong>April 2020 </strong>— minor update. The text in the definition of epilepsy has been clarified. </p><p><strong>February 2020</strong> — minor update. Recommendations about discussing the risk of antiepileptic drugs causing malformations and possible neurodevelopmental impairments in an unborn child, and to specifically discuss the risk of continued use of sodium valproate to the unborn child with women and girls of childbearing potential have been added to this topic in line with the updated NICE guideline <em>Epilepsies: diagnosis and management</em>. </p><p><strong>June to July 2019 </strong>— reviewed. A literature search was conducted in April 2019 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of this topic. No major changes to the recommendations have been made.</p><p>Text on valproate has been changed to reflect 2018 Medicines and Healthcare products Regulatory Agency advice regarding the use of valproate medicines in women and girls of childbearing potential. There have also been minor changes to the sections on assessment, management of a first seizure, contraception, and pregnancy.</p><p>Links to sources of patient information and support have been added where applicable.</p><!-- end field 62582180-70bc-4710-96c2-1219ceee87db --><!-- end item 7a7fd4ac-984b-469f-a677-36bbbbdd2e19 -->","topic":{"id":"f8129267-de9a-585d-9e33-8725cd832f5f","topicId":"b393b08f-0928-43ec-abde-ec6b4844fdee","topicName":"Epilepsy","slug":"epilepsy","lastRevised":"Last revised in January 2021","chapters":[{"id":"5b049e7f-5e24-5bcc-af53-ff98c396ad9e","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"6b88498d-4758-510e-afc3-ed87d1957cad","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"e31fe7a4-1ae2-5cd9-b804-0d4c44e53ebc","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"7a679807-bda2-5ee7-9bde-7ecdc0762be8","slug":"changes","fullItemName":"Changes"},{"id":"7e16f4d4-24ca-5628-ba07-c486b95e90c5","slug":"update","fullItemName":"Update"}]},{"id":"535dff27-4aaa-57fa-80a1-d274bd3b4e59","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"48265493-8622-58e8-a018-48a3e42f1148","slug":"goals","fullItemName":"Goals"},{"id":"6c194eb8-ba43-5a68-a78f-51161a41e8db","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"c76ab727-494d-527d-a154-b8c28b77d8a4","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"6d0101cf-ff01-5958-a6fb-ebfbd77e76fd","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"d111772f-1391-5d7f-a517-24a28715a449","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"30ff44ac-b721-5577-a601-8c4d55fa848d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"59735dcb-eba6-5d18-bea9-06c5d9c7b253","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"4966ce92-afe3-59eb-b304-caf674cc78ae","slug":"definition","fullItemName":"Definition"},{"id":"5bbc7943-77eb-54ab-a31a-50a8a32fb58b","slug":"causes","fullItemName":"Causes"},{"id":"2779c8f9-cdfd-5fc5-9a9e-ff78cc795095","slug":"prevalence","fullItemName":"Prevalence"},{"id":"d76a05be-28cf-51f2-9112-94a3089622ef","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"397d1dd0-2884-5fe1-93ec-86f60bb3f9b0","slug":"complications","fullItemName":"Complications"},{"id":"22457087-3e91-5c25-b650-d494bac54036","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"58d6be4c-1ac7-5b65-b78e-bff25e6e76e6","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"9854a4d4-10b2-54cb-bde8-bd6851a2a8d3","slug":"assessment","fullItemName":"Assessment"},{"id":"e24eacf4-0b1d-5c8e-beb3-8e4373ee4f96","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"0b45afa2-7eab-5f3c-baa9-bf2274759bb7","fullItemName":"Management","slug":"management","subChapters":[{"id":"ac1322eb-1276-5dd0-bc64-f83fe4b15961","slug":"suspected-epilepsy","fullItemName":"Scenario: Suspected epilepsy"},{"id":"e72ec2fc-c602-5ac7-9d71-792f49a18f1f","slug":"managing-an-epileptic-seizure","fullItemName":"Scenario: Managing an epileptic seizure"},{"id":"f0726760-8fbd-5900-8525-9c2c98180d5a","slug":"routine-epilepsy-review","fullItemName":"Scenario: Routine epilepsy review"},{"id":"c14abfdb-dd66-5da7-90f4-aed8bb06d929","slug":"women-of-childbearing-age","fullItemName":"Scenario: Women of childbearing age"}]},{"id":"dc732fc8-8397-5b8b-886e-654a3d37dedf","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a9cc1abe-202c-5ec3-9fa2-4bc1e9003e29","slug":"prescribing-antiepileptic-drugs","fullItemName":"Prescribing antiepileptic drugs"},{"id":"0a33c3f0-2ae8-515f-a2ce-2deeae71dba9","slug":"adverse-effects-of-antiepileptic-drugs","fullItemName":"Adverse effects of antiepileptic drugs"},{"id":"3b7a2ba0-89af-5839-8597-3c9290c9dc23","slug":"enzyme-inducing-antiepileptic-drugs","fullItemName":"Enzyme-inducing antiepileptic drugs"}]},{"id":"b4c758e3-f2ef-5920-8a4b-057ce3f83d8e","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"12d642de-145f-5602-a8e5-c6320aab1692","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"0cb744d0-8999-57a7-87e5-e25e4df6722a","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0ad13cb3-2b8b-56c4-824c-8f777375a7bf","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"17531a22-0a95-5a68-a007-18cb5384f001","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"6b27fc25-7d42-5230-a79b-0c623eb6b606","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"7dd141fa-9fe8-54b2-b10c-584815f12e6f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"4b23c7ea-9a6f-5491-aa41-741d7d52e107","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"e31fe7a4-1ae2-5cd9-b804-0d4c44e53ebc","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"1c55a703-2b4a-59c0-8470-10f23236ccc8","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 1be7c9e6-0456-4b0d-9946-e0df9f5c17e4 --><h3>Previous changes</h3><!-- end field 1be7c9e6-0456-4b0d-9946-e0df9f5c17e4 -->","summary":null,"htmlStringContent":"<!-- begin item c0c13dc0-6854-459a-ba30-4f6b87af13f4 --><!-- begin field 7e2edfc5-6510-4967-a6b8-56ba11ed3d1a --><p><strong>May 2018</strong> — minor update. New product availability - Brivaracetam oral solution and tablets have been approved as monotherapy or adjunctive therapy for partial-onset (focal) seizures in patients four years of age and older. </p><p><strong>April 2018 </strong>— minor update. Information added to adverse effects regarding Lamotrigine causing hemophagocytic lymphohistiocytosis.</p><p><strong>March 2018</strong> — minor update. Information added to adverse effects relating to prescribing semisodium valproate to patients with an underlying carnitine palmitoyltransferase type II deficiency.</p><p><strong>September 2017</strong> — minor update. Information added on laboratory tests in the adverse effects prescribing information section.</p><p><strong>September 2017</strong> — minor update. Information added to adverse effects for cardiovascular effects as per updates to the manufacturers' summary of product characteristics for phenytoin.</p><p><strong>December 2016</strong> — minor update.</p><ul><li>The section on adverse effects of antiepileptic drugs has been updated with the information that macular abnormality with features of vitelliform maculopathy occurs in some people taking retigabine. Information on worsening of convulsions has also been added.</li><li>Stevens–Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms (DRESS) have been added as possible adverse effects of lamotrigine. </li></ul><p><strong>November 2016</strong> — minor update. A Medicines and Healthcare products Regulatory Agency (MHRA) Drug safety update <em>Valproate and risk of abnormal pregnancy outcomes: new communication materials</em> recommendation to use new support tools to support discussion about the risks of valporate in pregnancy has been added to this topic.</p><p><strong>June 2015 </strong>— minor update. Nightmares added as an adverse effect of lamotrigine based on an update to the manufacturer's Summary of Product Characteristics (SPC).</p><p><strong>October to December 2014 </strong>— reviewed. A literature search was conducted in October 2014 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of this topic. The management sections have been restructured. No major changes to the recommendations have been made, which are in line with the National Institute for Health and Clinical Excellence (NICE) guideline <em>The epilepsies. The diagnosis and management of the epilepsies in adults and children in primary and secondary care  </em>2012), and a subsequent Evidence Update of the NICE guideline <em>The epilepsies </em>(2014).</p><p><strong>May 2014 </strong>— minor update. The word prescriptions has been removed from the 'How up to date is this topic?' section.</p><p><strong>December 2013 </strong>— minor update. A broken link to appendix G in the NICE guidance has been removed.</p><p><strong>November 2013 </strong>— minor update. Text updated in line with the Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update regarding switching between manufacturers' products of antiepileptic drugs, including switching between branded and generic products, and between different generic products of a particular antiepileptic drug.</p><p><strong>July 2013 </strong>— minor update. Links to the DVLA website have been updated.</p><p><strong>June 2013 </strong>— minor update. The 2013 QOF options for local implementation have been added to this topic.</p><p><strong>August 2012 </strong>— minor update. Minor typographical error corrected.</p><p><strong>March 2012 </strong>— minor update. The 2012/2013 QOF indicators have been added to this topic. Issued in April 2012.</p><p><strong>January 2012 </strong>— minor update. Topic updated to reflect relevant changes to the new epilepsy guidance <em>The Epilepsies</em>: <em>The diagnosis and management of the epilepsies in adults and children in primary and secondary care </em>issued by the National Institute for Health and Care Excellence. Issued in February 2012.</p><p><strong>June 2011 </strong>— minor update. Evidence from a large cohort study on dose-dependent risk of malformations with antiepileptic drugs added to the section on contraception and pregnancy planning. Issued in June 2011.</p><p><strong>May 2011 </strong>— minor update. The 2011/2012 QOF indicators have been added to this topic. Issued in June 2011.</p><p><strong>February 2011 </strong>— topic structure revised to ensure consistency across CKS topics — no changes to clinical recommendations have been made.</p><p><strong>February to June 2009 </strong>— converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. There have been no major changes to the recommendations.</p><p><strong>April 2009 </strong>— minor update. The section <em>GMS audit criteria </em>in the <em>Goals and outcome measures </em>section has been renamed <em>QOF indicators</em>. Issued in May 2009.</p><p><strong>January 2009 </strong>— minor update. Drug safety advice from the MHRA (Medicines and Healthcare products Regulatory Agency) that all antiepileptic drug treatment is associated with a small risk of suicidal thoughts and behaviour. Issued in February 2009.</p><p><strong>July to September 2005 </strong>— reviewed. Validated in December 2005. Issued in February 2006.</p><p><strong>April 2008 </strong>— updated to add new drug safety advice from the MHRA (Medicines and Healthcare products Regulatory Agency) on genetic testing for certain ethnic groups before starting carbamazepine, to reduce the risk of carbamazepine-induced Stevens-Johnson syndrome. Issued in May 2008.</p><p><strong>November 2007 </strong>— updated to add new drug safety advice from the MHRA (Medicines and Healthcare products Regulatory Agency) on the interaction between St John's wort and <em>all </em>antiepileptic drugs. Issued in December 2007.</p><p><strong>July 2005 </strong>— updated to incorporate <em>Referral guidelines for suspected cancer </em>published by NICE. Issued in July 2005.</p><p><strong>August 2004 </strong>— updated to incorporate NICE technology appraisal number 79, <em>Newer drugs for epilepsy in children</em>, and number 76, <em>Newer drugs for epilepsy in adults</em>. Validated in September 2004 and issued in November 2004.</p><p><strong>June 2003 </strong>— reviewed. Validated in September 2003 and issued in October 2003.</p><p><strong>October 2000 </strong>— updated to incorporate the Department of Health Referral Guidelines for Suspected Brain Tumour. Validated in November 2000 and issued in December 2000.</p><p><strong>July 1999 </strong>— written. Validated in October 1999 and issued in January 2000.</p><!-- end field 7e2edfc5-6510-4967-a6b8-56ba11ed3d1a --><!-- end item c0c13dc0-6854-459a-ba30-4f6b87af13f4 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}